Defective transcription elongation in a subset of cancers confers immunotherapy resistance

Vishnu Modur, Navneet Singh, Vakul Mohanty, Eunah Chung, Belal Muhammad, Kwangmin Choi, Xiaoting Chen, Kashish Chetal, Nancy Ratner, Nathan Salomonis, Matthew T. Weirauch, Susan Waltz, Gang Huang, Lisa Privette-Vinnedge, Joo Seop Park, Edith M. Janssen, Kakajan Komurov

Resultado de la investigación: Articlerevisión exhaustiva

12 Citas (Scopus)

Resumen

The nature and role of global transcriptional deregulations in cancers are not fully understood. We report that a large proportion of cancers have widespread defects in mRNA transcription elongation (TE). Cancers with TE defects (TEdeff) display spurious transcription and defective mRNA processing of genes characterized by long genomic length, poised promoters and inducible expression. Signaling pathways regulated by such genes, such as pro-inflammatory response pathways, are consistently suppressed in TEdeff tumors. Remarkably, TEdeff correlates with the poor response and outcome in immunotherapy, but not chemo- or targeted therapy, -treated renal cell carcinoma and metastatic melanoma patients. Forced pharmacologic or genetic induction of TEdeff in tumor cells impairs pro-inflammatory response signaling, and imposes resistance to the innate and adaptive anti-tumor immune responses and checkpoint inhibitor therapy in vivo. Therefore, defective TE is a previously unknown mechanism of tumor immune resistance, and should be assessed in cancer patients undergoing immunotherapy.

Idioma originalEnglish (US)
Número de artículo4410
PublicaciónNature communications
Volumen9
N.º1
DOI
EstadoPublished - dic. 1 2018
Publicado de forma externa

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • General
  • Physics and Astronomy(all)

Huella

Profundice en los temas de investigación de 'Defective transcription elongation in a subset of cancers confers immunotherapy resistance'. En conjunto forman una huella única.

Citar esto